Eleven Biotherapeutics Inc. (EBIO) Stock Price Down 1.2%
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) shares were down 1.2% during trading on Tuesday . The stock traded as low as $2.40 and last traded at $2.49, with a volume of 821,991 shares traded. The stock had previously closed at $2.52.
The company has a 50-day moving average of $1.96 and a 200 day moving average of $1.11. The firm’s market cap is $38.79 million.
In related news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of the business’s stock in a transaction on Monday, June 13th. The shares were sold at an average price of $2.74, for a total value of $2,855,080.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.